monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
Published 2 years ago • 404 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
1:26
monarche: investigating adjuvant abemacicilib for high-risk hr breast cancer
-
1:08
4-year monarche results: increasing benefits with abemaciclib et for er /her2- high-risk early bc
-
1:04
5-year monarche results: abemaciclib et in high-risk ebc
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
4:19
monarche results: abemaciclib plus endocrine therapy in high-risk early breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
3:06
age-stratified findings from the monarche trial of abemaciclib in breast cancer
-
1:59
monarche: patient-reported outcomes
-
4:28
asco 2023 highlights in breast cancer: natalee, monarche, and penelope-b
-
1:48
natalee and monarche: ribociclib and abemaciclib in hr /her2- breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
4:45
monarch 3: abemaciclib as initial therapy for patients with hr /her2- advanced breast cancer
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
29:10
adjuvant abemaciclib/ribociclib #monarche/natalee #best treatment for breast cancer #cdk 4/6 -cure
-
5:12
monarch 2: abemaciclib added to fulvestrant shows os benefit in hr /her2- advanced breast cancer